Biggest changeThe following table sets forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods presented: GoHealth, Inc. 2023 Form 10-K 48 Twelve months ended Dec. 31, Non-GAAP Financial Measures 2023 2022 2021 Net revenues $ 734,671 $ 631,675 $ 1,062,415 Net income (loss) (151,270) (376,384) (534,194) Interest expense 69,472 57,069 33,505 Income tax expense (benefit) 154 764 (24) Depreciation and amortization expense 105,748 107,002 107,507 EBITDA 24,104 (211,549) (393,206) Share-based compensation expense (benefit) (1) 19,564 32,124 27,297 Legal fees (2) 14,840 3,478 180 Operating lease impairment charges (3) 2,687 25,345 1,062 Severance costs (4) 1,920 3,340 — Professional services (5) 1,548 4,752 — Restructuring and other related charges (6) — 12,184 — Other (income) loss related to the adjustment of liabilities under the Tax Receivable Agreement (7) 428 550 — Loss on extinguishment of debt (8) — — 11,935 Goodwill and intangible asset impairment charges (9) 10,000 — 386,553 Adjusted EBITDA $ 75,091 $ (129,776) $ 33,821 Adjusted EBITDA margin 10.2 % (20.5) % 3.2 % (1) Represents non-cash share-based compensation expense (benefit) relating to equity awards as well share-based compensation expense (benefit) relating to liability classified awards that will be settled in cash.
Biggest changeThe following table sets forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods presented: GoHealth, Inc. 2024 Form 10-K 50 Twelve months ended Dec. 31, Non-GAAP Financial Measures 2024 2023 2022 Net revenues $ 798,894 $ 734,671 $ 631,675 Net income (loss) (7,319) (151,270) (376,384) Interest expense 72,868 69,472 57,069 Income tax expense (benefit) 2,267 154 764 Depreciation and amortization expense 105,890 105,748 107,002 EBITDA 173,706 24,104 (211,549) Gain on bargain purchase 1 (84,492) — — Share-based compensation expense 2 11,281 19,564 32,124 Loss on extinguishment of debt 3 10,463 — — Professional services 4 3,671 1,548 4,752 Legal fees 5 2,917 14,840 3,478 Severance costs 6 2,480 1,920 3,340 Other (income) loss related to the adjustment of liabilities under the Tax Receivable Agreement 7 293 428 550 Operating lease impairment charges 8 — 2,687 25,345 Restructuring and other related charges 9 — — 12,184 Intangible asset impairment charges 10 — 10,000 — Adjusted EBITDA $ 120,319 $ 75,091 $ (129,776) Net income (loss) margin (0.9) % (20.6) % (59.6) % Adjusted EBITDA margin 15.1 % 10.2 % (20.5) % (1) Represents the excess of the acquisition-date fair value of the net assets acquired over the acquisition-date fair value of the consideration transferred related to the acquisition of e-TeleQuote, as further described in Note 15, Acquisitions.
Each consenting lender received a 50% commitment reduction, resulting in a total of $88.5 million available to the Company under the New Class A Revolving Commitments, with $23.5 million remaining available to the Company under the Remaining Class B Revolving Commitments.
Each consenting lender received a 50% commitment reduction, resulting in a total of $88.5 million available to the Company under the New Class A Revolving Commitments, with $23.0 million remaining available to the Company under the Class B Revolving Commitments.
SARs are liability-classified awards, and as such, are recorded as a liability on the Consolidated Balance Sheet. The assumptions we use represent management's best estimates. If factors change and different assumptions are used, our compensation expense for stock options could be materially different for future grants. See Note 7, “Share-Based Compensation Plans,” for further discussion of share-based compensation.
SARs are liability-classified awards, and as such, are recorded as a liability on the Consolidated Balance Sheets. The assumptions we use represent management's best estimates. If factors change and different assumptions are used, our compensation expense for stock options could be materially different for future grants. See Note 7, “Share-Based Compensation Plans,” for further discussion of share-based compensation.
During the twelve months ended December 31, 2023, 2022 and 2021, the Company was actively looking to terminate or sublease certain office spaces and call centers that were deemed no longer economically beneficial to the Company. As a result, these properties are considered individual asset groups for the purpose of testing for impairment.
During the twelve months ended December 31, 2024, 2023 and 2022, the Company was actively looking to terminate or sublease certain office spaces and call centers that were deemed no longer economically beneficial to the Company. As a result, these properties are considered individual asset groups for the purpose of testing for impairment.
Marketing and advertising expenses are generally higher in the fourth quarter during AEP, but because commissions from approved customers are paid to us over time, our operating cash flows could be adversely impacted by a substantial increase in marketing and advertising expenses as a result of a higher volume of Submissions during the fourth quarter or positively impacted by a substantial decline in marketing and advertising expenses as a result of lower volume of Submissions during the fourth quarter.
Marketing and advertising expenses are generally higher in the fourth quarter during AEP, but because commissions from approved consumers are paid to us over time, our operating cash flows could be adversely impacted by a substantial increase in marketing and advertising expenses as a result of a higher volume of Submissions during the fourth quarter or positively impacted by a substantial decline in marketing and advertising expenses as a result of lower volume of Submissions during the fourth quarter.
With a widely scalable end-to-end platform and substantial presence in the Medicare landscape, we believe we are uniquely positioned as a trusted partner to the 65 million Medicare-eligible Americans, as well as the 11,000 Americans becoming eligible each day, as they navigate one of life's most important purchasing decisions.
With a widely scalable end-to-end platform and substantial presence in the Medicare landscape, we believe we are uniquely positioned as a trusted partner to the 67 million Medicare-eligible Americans, as well as the 11,000 Americans becoming eligible each day, as they navigate one of life's most important purchasing decisions.
Factors that could cause such differences are discussed in the sections titled “Cautionary Note Regarding Forward-Looking Statements,” “Summary Risk Factors” and “Risk Factors” in this Annual Report on Form 10-K. The risks and uncertainties described in this 2023 Annual Report on Form 10-K are not the only risks and uncertainties we face.
Factors that could cause such differences are discussed in the sections titled “Cautionary Note Regarding Forward-Looking Statements,” “Summary Risk Factors” and “Risk Factors” in this Annual Report on Form 10-K. The risks and uncertainties described in this 2024 Annual Report on Form 10-K are not the only risks and uncertainties we face.
Term Loan Facilities As of December 31, 2023, the Company had a principal amount of $110.4 million, $296.3 million, and $96.1 million outstanding under the Incremental Term Loan Facility, the 2021 Incremental Term Loans, and the 2021-2 Incremental Term Loans, respectively. The Incremental Term Loan Facility effective interest rate was 13.0% and 11.2% at December 31, 2023 and 2022, respectively.
As of December 31, 2023, the Company had a principal amount of $110.4 million, $296.3 million and $96.1 million outstanding under the Incremental Term Loan Facility, 2021 Incremental Term Loans and 2021-2 Incremental Term Loans, respectively. The effective interest rate of the Term Loan Facilities was 13.0% at December 31, 2023.
The Company had no amounts outstanding under the Class A Revolving Credit Facilities and Class B Revolving Credit Facilities as of both December 31, 2023 and December 31, 2022. The Revolving Credit Facilities had a remaining capacity of $200.0 million in the aggregate as of both December 31, 2023 and December 31, 2022.
The Company had no amounts outstanding under the Class A Revolving Credit Facilities and Class B Revolving Credit Facilities as of December 31, 2023. The Class A Revolving Credit Facilities and Class B Revolving Credit Facilities had a remaining capacity of $200.0 million in the aggregate as of December 31, 2023.
As a result, we experience an increase in the number of Submissions during the fourth quarter and an increase in expense related to the Medicare Submissions during the third and fourth quarters.
As a result, and in general, we experience an increase in the number of Submissions during the fourth quarter and an increase in expense related to the Submissions during the third and fourth quarters.
See Note 5, “Long-Term Debt,” to the Consolidated Financial Statements in this Annual Report on Form 10-K for additional information regarding the Company’s Credit Facilities. Seasonality GoHealth, Inc. 2023 Form 10-K 53 The Medicare annual enrollment period (“AEP”) occurs from October 15 th to December 7 th .
GoHealth, Inc. 2024 Form 10-K 55 See Note 5, “Long-Term Debt,” to the Consolidated Financial Statements in this Annual Report on Form 10-K for additional information regarding the Company’s Credit Facilities. Seasonality The Medicare annual enrollment period (“AEP”) occurs from October 15 th to December 7 th .
As a result, during the twelve months ended December 31, 2023, we recorded indefinite-lived trade names impairment charges of $10.0 million to write down the carrying value of the indefinite-lived trade names to their fair value of $73.0 million.
As a result, during the twelve months ended December 31, 2023, we recorded an indefinite-lived trade names impairment charge of $10.0 million to write down the carrying value of the indefinite-lived trade names to their fair value of $73.0 million.
A discussion and analysis regarding our results of operations for fiscal year 2022 compared to fiscal year 2021 that are not included in this Annual Report on Form 10-K can be found in our Annual Report on Form 10-K filed with the SEC on March 23, 2023.
A discussion and analysis regarding our results of operations for fiscal year 2023 compared to fiscal year 2022 that are not included in this Annual Report on Form 10-K can be found in our Annual Report on Form 10-K filed with the SEC on March 14, 2024.
See Note 5, “Long-Term Debt,” to the Consolidated Financial Statements in this Annual Report on Form 10-K for additional information regarding the Company’s Term Loan Facility.
See Note 5, “Long-Term Debt,” to the Consolidated Financial Statements in this Annual Report on Form 10-K for additional information regarding the Company’s term loans.
The New Class A Revolving Commitments mature on June 30, 2025 and bear interest at either ABR plus 5.50% per annum or SOFR plus 6.50% per annum. The Remaining Class B Revolving Commitments continue to mature on September 13, 2024 and bear interest at either ABR plus 3.00% per annum or SOFR plus 4.00% per annum.
The New Class A Revolving Commitments mature on June 30, 2025 and bear interest at either ABR plus 5.50% per annum or SOFR plus 6.50% per annum. The remaining Class B Revolving Commitments matured on September 13, 2024 and bore interest at either ABR plus 3.00% per annum or SOFR plus 4.00% per annum.
During the twelve months ended December 31, 2023, 2022 and 2021, Non-Encompass BPO Services contributed $9.3 million, $87.4 million and $145.2 million to net revenues, respectively. During the first quarter of 2023, the Company reorganized its operations from four operating and reportable segments to one operating and reportable segment.
During the twelve months ended December 31, 2024, Non-Encompass BPO Services contributed no revenues. During the twelve months ended December 31, 2023 and 2022, Non-Encompass BPO Services contributed $9.3 million and $87.4 million to net revenues, respectively. During the first quarter of 2023, the Company reorganized its operations from four operating and reportable segments to one operating and reportable segment.
The weighted average ownership percentages for the applicable reporting periods are used to attribute net income (loss) and other comprehensive income (loss) to the Company and the non-controlling interest holders. The non-controlling interest holders' weighted average ownership percentages for the twelve months ended December 31, 2023, 2022, and 2021 were 58.2%, 61.1% and 67.0%, respectively.
The weighted average ownership percentages for the applicable reporting periods are used to attribute net income (loss) and other comprehensive income (loss) to the Company and the non-controlling interest holders. The non-controlling interest holders' weighted average ownership percentages for the twelve months ended December 31, 2024, 2023, and 2022 were 56.2%, 58.2% and 61.1%, respectively.
These non-GAAP financial measures include net income (loss) before interest expense, income tax (benefit) expense and depreciation and amortization expense, or EBITDA; Adjusted EBITDA; Adjusted EBITDA margin; Sales per Submission; Cost per Submission and Adjusted Gross Margin per Submission. Adjusted EBITDA is the primary financial performance measure used by management to evaluate its business and monitor its results of operations.
These non-GAAP financial measures include net income (loss) before interest expense, income tax (benefit) expense and depreciation and amortization expense, or EBITDA, Adjusted EBITDA and Adjusted EBITDA margin, Adjusted EBITDA is the primary financial performance measure used by management to evaluate the business and to monitor its results of operations.
Share-based compensation expense for Time-Vesting Units, RSUs, stock options and PSUs are recognized on a straight-line GoHealth, Inc. 2023 Form 10-K 54 basis over the requisite service or performance period, which is generally three to five years. We recognize forfeitures as they occur. The fair value of Time-Vesting Units and market-based PSUs are determined using a Monte Carlo simulation.
Share-based compensation expense for Time-Vesting Units, RSUs, stock options and PSUs are recognized on a straight-line basis over the requisite service or performance period, which is generally three to five years. We recognize forfeitures as they occur. The fair value of Time-Vesting Units and market-based PSUs are determined using a Monte Carlo simulation.
GoHealth, Inc. 2023 Form 10-K 44 Additionally, the Company made the strategic decision to exit its non-Encompass BPO Services, or services in which we dedicate certain agents to specific health plan partners and agencies outside of the Encompass model, to focus on our core business. The exit was completed during the second quarter of 2023.
Additionally, the Company made the strategic decision to exit its Non-Encompass BPO Services, or services in which we dedicate certain agents to specific health plan partners and agencies outside of the Encompass model, to focus on our core business. The exit was completed during the second quarter of 2023.
Amortization of intangible assets Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 94,057 $ 94,057 $ — — % 12.8% 14.9% Amortization of intangible assets expense was $94.1 million for both the twelve months ended December 31, 2023 and 2022, and relates to the amortization of developed technology and customer relationships.
Amortization of intangible assets Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 94,057 $ 94,057 $ — — % 11.8% 12.8% Amortization of intangible assets expense was $94.1 million for both the twelve months ended December 31, 2024 and 2023, and relates to the amortization of developed technology and customer relationships.
Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially adversely GoHealth, Inc. 2023 Form 10-K 43 affect our business, financial condition, or results of operations. We assume no obligation to update any of these forward-looking statements. Unless otherwise noted, all dollars are in thousands.
Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially adversely affect our business, financial condition, or results of operations. We assume no obligation to update any of these forward-looking statements. Unless otherwise noted, all dollars are in thousands.
GoHealth, Inc. 2023 Form 10-K 45 Results of Operations The following is a discussion and analysis of changes in the financial condition and results of operations for fiscal year 2023 compared to fiscal year 2022.
GoHealth, Inc. 2024 Form 10-K 47 Results of Operations The following is a discussion and analysis of changes in the financial condition and results of operations for fiscal year 2024 compared to fiscal year 2023.
Additionally, as a result of the annual Medicare Advantage open enrollment period that occurs from January 1 st to March 31 st , Medicare Submissions are typically second-highest in our first quarter. The second and third quarters are known as special election periods and are our seasonally smallest quarters.
Additionally, as a result of the annual Medicare Advantage open enrollment period that occurs from January 1 st to March 31 st , Submissions are typically second-highest in the first quarter. The second and third quarters are known as special election periods, during which Submissions are typically lowest.
Sales Per Submission Sales per Submission represents (x) the sum of (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, (ii) Encompass revenue, and (iii) partner marketing and enrollment services, divided by (y) the number of Submissions for such period, as reported above.
Sales per Submission refers to (x) the sum of (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, (ii) non-agency revenue and (iii) partner marketing and other revenue, divided by (y) the number of Submissions for such period.
At December 31, 2023, cash and cash equivalents totaled $90.8 million. We believe that our current sources of liquidity, which include cash and cash equivalents and funds available under the Credit Facilities, as described further below, will be sufficient to meet our projected operating and debt service requirements for at least the next twelve months.
We believe that our current sources of liquidity, which include cash and cash equivalents and funds available under the Credit Facilities, as described further below, will be sufficient to meet our projected operating and debt service requirements for at least the next twelve months.
Share-Based Compensation We grant share-based awards to employees and non-employee directors. Share-based awards include time-vesting profits units (“Time-Vesting Units”), restricted stock units (“RSUs”), stock options, performance stock units (“PSUs”) and stock appreciation rights ("SARs").We recognize compensation expense for all share-based awards based on the estimated grant date fair value.
Share-Based Compensation GoHealth, Inc. 2024 Form 10-K 56 We grant share-based awards to employees and non-employee directors. Share-based awards include time-vesting profits units (“Time-Vesting Units”), restricted stock units (“RSUs”), stock options, performance stock units (“PSUs”) and stock appreciation rights ("SARs"). We recognize compensation expense for all share-based awards based on the estimated grant date fair value.
GoHealth, Inc. 2023 Form 10-K 55 The fair values were estimated using a discounted cash flow approach on forecasted future cash flows expected to be derived from the property based on current sublease market rent, which is considered a level 3 input in the fair value hierarchy.
The fair values were estimated using a discounted cash flow approach on forecasted future cash flows expected to be derived from the property based on current sublease market rent, which is considered a level 3 input in the fair value hierarchy.
Operating lease impairment charges Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 2,687 $ 25,345 $ (22,658) (89.4) % 0.4% 4.0% As part of our continued cost savings initiatives, we are actively looking to terminate or sublease certain office spaces and call centers.
Operating lease impairment charges Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ — $ 2,687 $ (2,687) (100.0) % —% 0.4% As part of our continued cost savings initiatives, we are actively looking to terminate or sublease certain office spaces and call centers.
These actions resulted in $2.7 million in operating lease impairment charges during the twelve months ended December 31, 2023 and $25.3 million in operating lease impairment charges during the twelve months ended December 31, 2022.
These actions resulted in $2.7 million in operating lease impairment charges during the twelve months ended December 31, 2023.
Goodwill and intangible asset impairment charges Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 10,000 $ — $ 10,000 NM 1.4% —% During the twelve months ended December 31, 2023, the Company recorded an impairment charge of $10.0 million to write down the carrying value of the indefinite-lived trade names intangible asset to its fair value of $73.0 million.
Intangible asset impairment charges Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ — $ 10,000 $ (10,000) (100.0) % —% 1.4% During the twelve months ended December 31, 2023, we recorded an impairment charge of $10.0 million to write down the carrying value of the indefinite-lived trade names intangible asset to its fair value of $73.0 million.
See Note 4 "Goodwill and Intangible Assets, Net" for further discussion of our intangible assets. Impairment of Operating Lease ROU Assets The Company reviews operating lease right-of-use (“ROU”) assets, in conjunction with other long-lived assets, for impairment when facts or circumstances indicate the carrying amount of an asset or asset group may not be recoverable.
Impairment of Operating Lease ROU Assets The Company reviews operating lease right-of-use (“ROU”) assets, in conjunction with other long-lived assets, for impairment when facts or circumstances indicate the carrying amount of an asset or asset group may not be recoverable.
The following table presents a summary of cash flows for the twelve months ended December 31, 2023, 2022, and 2021; Twelve months ended Dec. 31, (in thousands) 2023 2022 2021 Net cash provided by (used in) operating activities $ 109,141 $ 60,904 $ (299,006) Net cash used in investing activities $ (13,732) $ (13,512) $ (19,801) Net cash (used in) provided by financing activities $ (21,106) $ (115,051) $ 259,089 Operating Activities Cash provided by (used in) operating activities primarily consists of net income (loss) adjusted for certain non-cash items including share-based compensation, depreciation and amortization, amortization of intangible assets, amortization of debt discount and issuance costs, goodwill and intangible impairment charges, operating lease impairment charges, non-cash restructuring charges, non-cash lease expense and the effect of changes in working capital and other activities.
The following table presents a summary of cash flows for the twelve months ended December 31, 2024, 2023, and 2022; Twelve months ended Dec. 31, (in thousands) 2024 2023 2022 Net cash provided by (used in) operating activities $ (21,607) $ 109,141 $ 60,904 Net cash provided by (used in) investing activities $ 3,807 $ (13,732) $ (13,512) Net cash provided by (used in) financing activities $ (32,033) $ (21,106) $ (115,051) Operating Activities Cash provided by (used in) operating activities primarily consists of net income (loss) adjusted for certain non-cash items including share-based compensation, depreciation and amortization, amortization of intangible assets, amortization of debt discount and issuance costs, intangible impairment charges, loss on extinguishment of debt, operating lease impairment charges, deferred tax liability, non-cash restructuring charges, non-cash lease expense, gain on bargain purchase and the effect of changes in working capital and other activities.
The percentage ownership of total shares of Class A and Class B common stock issued and outstanding as of December 31, 2023, is as follows: The percentage of ownership noted above is inclusive of only Class A and Class B common stock issued and outstanding.
The percentage ownership of total shares of Class A and Class B common stock issued and outstanding as of December 31, 2024, is as follows: GoHealth, Inc. 2024 Form 10-K 46 The percentage of ownership noted above is inclusive of only Class A and Class B common stock issued and outstanding.
Agency revenue refers to the commissions revenue and partner marketing revenue we receive when GoHealth agents or our independent network of outsourced agents enroll the consumer and submit the policy application to the health plan partner, becoming the agent of record.
Agency revenue refers to the commission revenue and partner marketing revenue we receive when GoHealth’s internal agents or our external agents enroll the consumer and submit the policy application to the health plan partner, becoming the agent of record.
Net cash provided by operating activities was $109.1 million for the twelve months ended December 31, 2023, compared to $60.9 million for the twelve months ended December 31, 2022.
Net cash used in operating activities was $21.6 million for the twelve months ended December 31, 2024, compared to net cash provided by operating activities of $109.1 million for the twelve months ended December 31, 2023.
As a result, we launched our Encompass operating model, which is our preferred operating platform that puts the consumer at the center of all our activities, including how we market, support enrollment activities, provide administrative services, utilize our proprietary technology and ultimately deliver a high-quality solution to those we serve.
This shift emphasizes a more integrated and interactive approach to consumer care and reflects how our Encompass operating model puts the consumer at the center of all our activities, including how we market, support enrollment activities, provide administrative services, utilize our proprietary technology and ultimately deliver a high-quality solution to those we serve.
This increase was partially offset by a decrease in revenues associated with the strategic decision to exit our Non-Encompass BPO Services.
The increase was further offset by a decrease in revenues associated with the strategic decision to exit our Non-Encompass BPO Services, which was completed during the second quarter of 2023.
Persistency adjustments allow us to estimate renewal revenue only to the extent probable that a material reversal in revenue would not be expected to occur. These factors may result in varying values from period to period.
The persistency-adjusted renewal period is determined based on our historical experience and available industry and health plan partner historical data. Persistency adjustments allow us to estimate renewal revenue only to the extent probable that a material reversal in revenue would not be expected to occur. These factors may result in varying values from period to period.
With leading proprietary technology and consumer insights, our end-to-end Encompass model offers a differentiated way for Medicare beneficiaries to navigate the complex Medicare Advantage plan selection process and begin to utilize their new plan benefits with greater confidence.
We believe our end-to-end Encompass model offers a differentiated way for Medicare beneficiaries to navigate the complex Medicare Advantage plan selection process and begin to utilize their new plan benefits with greater confidence. The Encompass operating model supports all Medicare services, including agency and non-agency revenue.
To the extent that our current liquidity is insufficient to fund future activities, we may need to raise additional funds, which may include the sale of equity securities or through debt financing arrangements.
Short-term liquidity needs will primarily be funded through the Revolving Credit Facilities, as described further below, if necessary. To the extent that our current liquidity is insufficient to fund future activities, we may need to raise additional funds, which may include the sale of equity securities or through debt financing arrangements.
The following table sets forth the components of our results of operations for the periods presented: Twelve months ended Dec. 31, (in thousands) 2023 2022 2021 Net revenues $ 734,671 $ 631,675 $ 1,062,415 Operating expenses: Revenue share 158,961 187,670 239,335 Marketing and advertising expense 205,042 207,559 365,141 Customer care and enrollment 209,234 260,902 319,103 Technology expense 43,302 46,094 48,429 General and administrative 93,069 116,530 98,183 Amortization of intangible assets 94,057 94,057 94,056 Operating lease impairment charges 2,687 25,345 1,062 Restructuring and other related charges — 12,184 — Goodwill and intangible asset impairment charges 10,000 — 386,553 Total operating expenses 816,352 950,341 1,551,862 Income (loss) from operations (81,681) (318,666) (489,447) Interest expense 69,472 57,069 33,505 Loss on extinguishment of debt — — 11,935 Other (income) expense, net (37) (115) (669) Income (loss) before income taxes (151,116) (375,620) (534,218) Income tax expense (benefit) 154 764 (24) Net income (loss) $ (151,270) (376,384) (534,194) Net income (loss) attributable to noncontrolling interests (88,013) (227,678) (344,837) Net income (loss) attributable to GoHealth, Inc. $ (63,257) $ (148,706) $ (189,357) Non-GAAP financial measures: EBITDA $ 24,104 $ (211,549) $ (393,206) Adjusted EBITDA $ 75,091 $ (129,776) $ 33,821 Adjusted EBITDA margin 10.2 % (20.5) % 3.2 % The following is our net revenues and results thereof for the twelve months ended December 31, 2023 and 2022: Net revenues Twelve months ended Dec. 31, 2023 2022 $ Change % Change $ 734,671 $ 631,675 $ 102,996 16.3 % The $103.0 million, or 16.3% increase compared to the prior year period was primarily attributable to an increase in non-agency revenue, which reflects our investment in enrollment and engagement service offerings along with the $110.3 million negative revenue adjustment in the prior year.
The following table sets forth the components of our results of operations for the periods presented: Twelve months ended Dec. 31, (in thousands) 2024 2023 2022 Net revenues $ 798,894 $ 734,671 $ 631,675 Operating expenses: Revenue share 130,612 158,961 187,670 Marketing and advertising expense 235,696 205,042 207,559 Consumer care and enrollment 222,414 209,234 260,902 Technology expense 41,046 43,302 46,094 General and administrative 82,116 93,069 116,530 Amortization of intangible assets 94,057 94,057 94,057 Operating lease impairment charges — 2,687 25,345 Intangible asset impairment charges — 10,000 — Restructuring and other related charges — — 12,184 Total operating expenses 805,941 816,352 950,341 Income (loss) from operations (7,047) (81,681) (318,666) Interest expense 72,868 69,472 57,069 Gain on bargain purchase (84,492) — — Loss on extinguishment of debt 10,463 — — Other (income) expense, net (834) (37) (115) Income (loss) before income taxes (5,052) (151,116) (375,620) Income tax expense (benefit) 2,267 154 764 Net income (loss) (7,319) (151,270) (376,384) Net income (loss) attributable to noncontrolling interests (4,391) (88,013) (227,678) Net income (loss) attributable to GoHealth, Inc. $ (2,928) $ (63,257) $ (148,706) Non-GAAP financial measures: EBITDA $ 173,706 $ 24,104 $ (211,549) Adjusted EBITDA $ 120,319 $ 75,091 $ (129,776) Net income (loss) margin (0.9) % (20.6) % (59.6) % Adjusted EBITDA margin 15.1 % 10.2 % (20.5) % The following is our net revenues and results thereof for the twelve months ended December 31, 2024 and 2023: Net revenues Twelve months ended Dec. 31, 2024 2023 $ Change % Change $ 798,894 $ 734,671 $ 64,223 8.7 % The $64.2 million, or 8.7% increase compared to the prior year period was primarily attributable to an increase in agency revenue driven by an increase in Submissions for which GoHealth is the agent of record, partially offset by a decrease in non-agency revenue.
Under the terms of Amendment No. 11, the lenders consenting to the extension formed a new tranche of Class A Revolving Commitments (the “New Class A Revolving Commitments”) and the non-consenting lenders remain part of the existing Class B Revolving Commitments (the “Remaining Class B Revolving Commitments”).
Pursuant to Amendment No. 11, effective March 12, 2024, lenders consenting to an extension to the maturity of their respective commitments formed a new tranche of Class A Revolving Commitments (the “New Class A Revolving Commitments”) and the non-consenting lenders remained part of the existing Class B Revolving Commitments.
Investing Activities Net cash used in investing activities increased to $13.7 million for the twelve months ended December 31, 2023, from $13.5 million for the twelve months ended December 31, 2022. The change was driven by an increase in capitalized internal-use software related to new technology, software and systems.
The change was primarily driven by the acquisition of e-TeleQuote, partially offset by an increase in capitalized internal-use software related to new technology, software and systems. Financing Activities Net cash used in financing activities was $32.0 million for the twelve months ended December 31, 2024, from $21.1 million for the twelve months ended December 31, 2023.
Recent Accounting Pronouncements For a discussion of new accounting pronouncements recently adopted, see Note 1. “Description of Business and Significant Accounting Policies,” to the Consolidated Financial Statements included in Item 8 to this Annual Report on Form 10-K. Liquidity and Capital Resources Overview GoHealth, Inc. 2023 Form 10-K 51 Our liquidity needs primarily include working capital and debt service requirements.
“Description of Business and Significant Accounting Policies,” to the Consolidated Financial Statements included in Item 8 to this Annual Report on Form 10-K. Liquidity and Capital Resources GoHealth, Inc. 2024 Form 10-K 53 Overview Our liquidity needs primarily include working capital and debt service requirements. At December 31, 2024, cash and cash equivalents totaled $40.9 million.
Intangible Assets Our trade names asset is an indefinite-lived intangible asset tested for impairment on November 30 th of each year or whenever events or changes in circumstances indicate that an impairment may exist. If the carrying amount of our indefinite-lived intangible trade names exceeds its fair value, an impairment loss is recognized in an amount equal to that excess.
Intangible Assets Our trade names asset is an indefinite-lived intangible asset tested for impairment, using either a qualitative or quantitative approach, on November 30 th of each year or whenever events or changes in circumstances indicate that an impairment may exist.
PlanFit CheckUp enables consumers to navigate this crowded space, regularly assessing the appropriateness of their current plan through a data-driven customized process, guided by the trusted expertise of a licensed GoHealth agent.
PlanFit CheckUp enables consumers to regularly assess the appropriateness of their current plan through a data-driven customized process, guided by the trusted expertise of a licensed GoHealth agent. In addition to further developing PlanFit Checkups, we are investing in technologies like Customer 360.
We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and include other expenses, costs and non-routine items.
In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and may include other expenses, costs and non-routine items.
Reconciliations of each of EBITDA, Adjusted EBITDA, Sales per Submission, Cost per Submission and Adjusted Gross Margin per Submission to its most directly comparable GAAP financial measure, are presented in the tables below in this Annual Report on Form 10-K.
Reconciliations of EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin to their most directly comparable GAAP financial measures are presented in the tables furnished below in this Annual Report on Form 10-K. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented.
Recoverability of these assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the assets are expected to generate from their use and eventual disposition. If such review indicates that the carrying amount of intangible assets is not recoverable, the carrying amount of such assets is reduced to fair value.
Intangible assets subject to amortization are also evaluated for impairment when indicators of impairment are determined to exist. Recoverability of these assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the assets are expected to generate from their use and eventual disposition.
See “Risk Factors—Risks Related to Our Business—Our operating results may be adversely impacted by factors that impact our estimate of LTV” in this Annual Report on Form 10-K.
See “Risk Factors—Risks Related to Our Business—Our operating results may be adversely impacted by factors that impact our estimate of LTV” in this Annual Report on Form 10-K. Agency revenue includes partner marketing revenue, in which the Company is compensated by its health plan partners for providing marketing services over a predetermined measurement period.
The enrollment and engagement services offered through our non-agency model are strategically designed to enhance the consumer experience, reflecting our increased focus on building trusted, long-term relationships with our consumers. The growth of non-agency revenue from prior year periods reflects our commitment to a consumer-centric approach.
The enrollment and engagement services offered through our non-agency model are strategically designed to enhance the consumer experience, reflecting our focus on building trusted, long-term relationships with our consumers. Non-agency revenue for the twelve months ended December 31, 2024 represented 27% of total Medicare revenue compared to 38% of total Medicare revenue for the twelve months ended December 31, 2023.
Non-agency revenue refers to services we provide that support enrollment and engagement activities in which GoHealth is not the agent of record.
Non-agency revenue refers to services our internal agents or our external agents provide that support enrollment and engagement activities in which GoHealth is not the agent of record. The non-agency model moves away from the agency structure in that cash is collected in advance or in close proximity to the point in time revenue is recognized.
Submissions Submissions are counted when an individual either (i) completes an application with our licensed agent that is submitted to the health plan partner and subsequently approved by the health plan partner during the indicated period, excluding applications through our Non-Encompass BPO Services or (ii) is transferred by our agent to the health plan partner through the Encompass marketplace during the indicated period.
The following are our Submissions, Sales per Submission and Direct Operating Cost per Submission for the periods presented: Twelve months ended Dec. 31, 2024 2023 2022 Submissions 1,016,182 826,159 862,656 Sales per Submission $ 781 $ 866 $ 915 Direct Operating Cost per Submission $ 578 $ 683 $ 747 Submissions GoHealth, Inc. 2024 Form 10-K 51 Submissions are counted when an individual either (i) completes an application with our licensed agent that is submitted to the health plan partner and subsequently approved by the health plan partner during the indicated period, excluding applications through our Non-Encompass BPO Services or (ii) is transferred by our agent to the health plan partner through the Encompass marketplace during the indicated period.
Interest expense Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 69,472 $ 57,069 $ 12,403 21.7 % 9.5% 9.0% The $12.4 million, or 21.7% increase was primarily attributable to an increase in interest rates on our Term Loan Facilities.
GoHealth, Inc. 2024 Form 10-K 49 Interest expense Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 72,868 $ 69,472 $ 3,396 4.9 % 9.1% 9.5% The $3.4 million, or 4.9% increase was primarily attributable to an increase in interest expense related to our outstanding Revolving Credit Facilities.
General and administrative Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 93,069 $ 116,530 $ (23,461) (20.1) % 12.7% 18.4% The $23.5 million, or 20.1% decrease was primarily attributable to an $11.4 million decrease in share-based compensation expense a $7.6 million decrease in expense related to employee incentive compensation, a $3.7 million decrease in expenses related to consulting fees, a $3.3 million decrease in expenses related to corporate insurance and a $2.5 million decrease in depreciation expense, partially offset by a $7.5 million increase in expenses related to legal fees.
General and administrative Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 82,116 $ 93,069 $ (10,953) (11.8) % 10.3% 12.7% The $11.0 million, or 11.8% decrease was primarily attributable to a decrease in expense related to legal fees for the Securities Class Action (as defined and discussed further in Note 12, “Commitments and Contingencies”) and a decrease in share-based compensation expense, partially offset by an increase in cost associated with the e-TeleQuote acquisition.
As of December 31, 2023 and December 31, 2022, the Company determined that a $0.8 million and $0.6 million liability related to the TRA arose from the Transactions, respectively. Should the Company determine that any additional TRA liability is considered probable at a future date based on new information, any changes will be recorded within earnings at that time.
Should the Company determine that any additional Tax Receivable Agreement liability is considered probable at a future date based on new information, any changes will be recorded within earnings at that time. See Note 9, “Income Taxes” for further discussion of the TRA.
As a result of the impairment testing over certain operating lease ROU assets, the Company recorded operating lease impairment charges of $2.7 million, $25.3 million and $1.1 million for the twelve months ended December 31, 2023, 2022 and 2021, respectively. See Note 3, “Fair Value Measurements,” for further discussion around fair value determinations.
There are additional estimates and assumptions used to arrive at estimated future cash flows, including discount rate, downtime, abatement and commissions. As a result of the impairment testing over certain operating lease ROU assets, the Company recorded operating lease impairment charges of $2.7 million and $25.3 million for the twelve months ended December 31, 2023 and 2022, respectively.
Technology expense Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 43,302 $ 46,094 $ (2,792) (6.1) % 5.9% 7.3% The $2.8 million, or 6.1% decrease was primarily attributable to reduced headcount in our technology support functions, partially offset by the third quarter technological enhancements in preparation for the 2023 AEP.
Technology expense Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 41,046 $ 43,302 $ (2,256) (5.2) % 5.1% 5.9% The $2.3 million, or 5.2% decrease was primarily attributable to a decrease in share-based compensation expense for technology employees.
The following are our key components of operating expenses and results thereof for the twelve months ended December 31, 2023 and 2022: Revenue share Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 158,961 $ 187,670 $ (28,709) (15.3) % 21.6% 29.7% The $28.7 million, or 15.3% decrease was primarily attributable to declines in certain direct partner campaigns with revenue-sharing components.
The following are our key components of operating expenses and results thereof for the twelve months ended December 31, 2024 and 2023: Revenue share Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 130,612 $ 158,961 $ (28,349) (17.8) % 16.3% 21.6% GoHealth, Inc. 2024 Form 10-K 48 The $28.3 million, or 17.8% decrease was primarily driven by a decrease in Submissions generated by our external agents, which decreased the amount of expense we recognized pursuant to our revenue-sharing agreements with our external partners.
Financing Activities Net cash used in financing activities was $21.1 million for the twelve months ended December 31, 2023, from net cash used in financing activities of $115.1 million for the twelve months ended December 31, 2022.
Investing Activities Net cash provided by investing activities increased to $3.8 million for the twelve months ended December 31, 2024, from $13.7 million net cash used in investing activities for the twelve months ended December 31, 2023.
Prior to Amendment No. 11, the Revolving Credit Facilities were separated into two classes of revolving commitments consisting of Class A Revolving Commitments in the amount of $30.0 million (the “Class A Revolving Commitments”) and Class B Revolving GoHealth, Inc. 2023 Form 10-K 52 Commitments in the amount of $170.0 million (the “Class B Revolving Commitments”), each maturing on September 13, 2024.
Revolving Credit Facilities Through a series of amendments during 2020 and 2021, the Credit Agreement provided for a revolving credit facility in an aggregate principal amount of $200.0 million which was separated into two classes of revolving commitments consisting of Class A Revolving Commitments in the amount of $30.0 million and Class B Revolving Commitments in the amount of $170.0 million , each maturing on September 13, 2024.
Determination of fair value involves significant estimates and assumptions including, among others, cash flow projections and selecting appropriate royalty and discount rates. Intangible assets subject to amortization are also evaluated for impairment when indicators of impairment are determined to exist.
Determination of fair value involves significant estimates and assumptions including, among others, cash flow projections and selecting appropriate royalty and discount rates. We performed a qualitative assessment for our annual indefinite-lived impairment test performed as of November 30, 2024.
The $48.2 million increase was driven by an increase in net income of $225.1 million and an increase in cash from working capital components from accounts payable of $27.4 million and accrued liabilities of $32.4 million.
The $130.7 million decrease was primarily driven by a decrease in cash from working capital components from commissions receivable, other liabilities, accounts payable, accounts receivable and accrued liabilities.
Our improved operating efficiencies were enabled by reduced headcount, targeted marketing and enhancements in our proprietary technology. Key Business Performance and Operating Metrics In addition to traditional financial metrics, we rely upon certain business and operating metrics to evaluate our business performance and facilitate our operations.
Key Business Performance and Operating Metrics In addition to traditional financial metrics, we rely upon certain business and operating metrics to evaluate our business performance and facilitate our operations. The most relevant business and operating metrics for our single operating and reportable segment are furnished in the tables below (unaudited).
As of December 31, 2023, the Company had no amounts outstanding under the Revolving Credit Facilities and had a remaining capacity of $200.0 million, before the signing of Amendment No. 11 in March 2024, as described below. Outstanding borrowings under the Revolving Credit Facilities are now due and payable on June 30, 2025.
As of December 31, 2024 the Company had $30.0 million outstanding under the New Class A Revolving Credit Facility and no amounts outstanding under the Class A-1 Revolving Credit Facility. The New Class A Revolving Credit Facility and Class A-1 Revolving Credit Facility had a remaining capacity of $58.5 million and $35.0 million, respectively, as of December 31, 2024.
Adjusted EBITDA Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 75,091 $ (129,776) $ 204,867 157.9 % 10.2% (20.5)% The $204.9 million, or 157.9% increase for the twelve months ended December 31, 2023 compared to the prior year period was primarily due to our focus on driving high-quality Medicare services for our consumers through the Encompass operating model.
Adjusted EBITDA Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 120,319 $ 75,091 $ 45,228 60.2 % 15.1% 10.2% The $45.2 million, or 60.2% increase for the twelve months ended December 31, 2024 compared to the prior year period was primarily due to an increase in net revenues and improved operating efficiencies enabled by agent productivity, targeted marketing and enhancements in our proprietary technology.
Sales per Submission, Cost per Submission and Adjusted Gross Margin per Submission are key operating metrics used by management to understand the Company’s underlying financial performance and trends. Adjusted EBITDA represents, as applicable for the period, EBITDA as further adjusted for certain items summarized in the table below. Adjusted EBITDA margin represents Adjusted EBITDA divided by net revenues.
Adjusted EBITDA represents, as applicable for the period, EBITDA as further adjusted for certain items summarized in the table furnished below. Adjusted EBITDA Margin represents Adjusted EBITDA divided by net revenues. We use non-GAAP financial measures to supplement financial information presented on a GAAP basis.
Customer care and enrollment Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 209,234 $ 260,902 $ (51,668) (19.8) % 28.5% 41.3% The $51.7 million, or 19.8% decrease was primarily attributable to reduced agent headcount as we focused on improving operational efficiencies.
Consumer care and enrollment Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 222,414 $ 209,234 $ 13,180 6.3 % 27.8% 28.5% The $13.2 million, or 6.3% increase was primarily attributable to an increased agent headcount during the 2024 AEP associated with the e-TeleQuote acquisition.
(2) Represents non-routine legal fees, settlement accruals and other expenses unrelated to our corporate operations. (3) Represents operating lease impairment charges, reducing the carrying value of the associated ROU assets and leasehold improvements to the estimated fair values. (4) Represents costs associated with the termination of executive employment and associated fees unrelated to restructuring activities.
(7) Represents expense related to the measurement of our TRA obligation. (8) Represents operating lease impairment charges, reducing the carrying value of the associated ROU assets and leasehold improvements to the estimated fair values.
The estimate of the future renewal commissions is determined by using the contracted renewal commission rates constrained by a persistency-adjusted renewal period. The persistency-adjusted renewal period is determined based on our historical experience and available industry and health plan partner historical data.
Agency revenue refers to the expected amount of initial commission revenue and any renewal commissions to be paid from the health plan partners on such placement as long as the policyholder remains with the same insurance product. The estimate of the future renewal commissions is determined by using the contracted renewal commission rates constrained by a persistency-adjusted renewal period.
(5) Represents costs associated with non-routine consulting fees and other professional services. (6) Represents employee termination benefits and other associated costs related to restructuring activities, as described in Note 14. “ Restructuring Costs” of the Notes to Consolidated Financial Statements. (7) Represents expense related to the measurement of our TRA obligation.
(9) Represents employee termination benefits and other associated costs related to restructuring activities, as described in Note 14, “Restructuring Costs” of the Notes to Consolidated Financial Statements. (10) Represents an indefinite-lived intangible asset impairment charge for the twelve months ended December 31, 2023.
Marketing and advertising expense Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 205,042 $ 207,559 $ (2,517) (1.2) % 27.9% 32.9% The $2.5 million, or 1.2% decrease was primarily attributable to an intentional pullback on marketing and advertising spend as the Company focused on higher quality Submissions through targeted marketing.
Marketing and advertising expense Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 235,696 $ 205,042 $ 30,654 15.0 % 29.5% 27.9% The $30.7 million, or 15.0% increase was primarily attributable to an increase in our marketing and advertising spend to generate more qualified prospects, which contributed to an increase in Submissions generated by our internal agents.
The increase in Sales/Cost of Submission, the decrease in Cost of Submission and decrease in Cost per Submission for the twelve months ended December 31, 2023 compared to the prior year period was primarily attributable to our strategic shift towards the Encompass operating model with improved operating efficiencies.
The following table presents the Direct Operating Cost per Submission for the periods presented: Direct Operating Cost Per Submission Twelve months ended Dec. 31, 2024 2023 $ Change % Change $ 578 $ 683 $ (105) (15.4) % The decrease for the twelve months ended December 31, 2024 compared to the prior year period was primarily attributable to improvements in agent productivity through enhanced training programs and investment in our technology.
The decrease was primarily driven by a decrease in the repayment of outstanding debt compared to the prior year period, partially offset by the issuance of 50,000 shares of Series A redeemable convertible preferred stock for an aggregate purchase price of $50.0 million during the prior year period.
The increase was primarily driven by an increase in repayments of our Term Loan Facilities, an increase in payments related to debt issuance costs related to the Amended and Restated Credit Agreement, partially offset by an increase in borrowings under the Revolving Credit Facilities and a decrease in payments of preferred stock dividends compared to the prior year period.
The following table presents the number of Submissions for the periods presented: Submissions Twelve months ended Dec. 31, 2023 2022 $ Change % Change 826,159 862,656 (36,497) (4.2) % The decrease for the twelve months ended December 31, 2023 compared to the prior year period was partially driven by increased consumer shopping but reduced plan switching during the 2023 AEP as well as a decrease in agent headcount and associated opportunities resulting from our strategic focus on driving high-quality Medicare services and operational efficiencies.
The following table presents the number of Submissions for the periods presented: Submissions Twelve months ended Dec. 31, 2024 2023 $ Change % Change 1,016,182 826,159 190,023 23.0 % The increase for the twelve months ended December 31, 2024 compared to the prior year period was primarily attributable to an increase in Submissions generated by GoHealth’s internal network of agents, powered by our enhanced marketing efforts, investments in technology and an increased agent headcount as a result of the e-TeleQuote acquisition.
Principal repayment obligations are reduced by the amount of any prepayment, and as such, the $14.0 million prepayment during the second quarter of 2023 satisfied the Company’s principal repayment obligations through the second quarter of 2025. No other mandatory prepayments were required or made during the twelve months ended December 31, 2023.
During the twelve months ended December 31, 2024, the Borrower paid two prepayments totaling $75.0 million pursuant to Amendment No. 11. No other mandatory prepayments were required or made during the twelve months ended December 31, 2024, 2023 or 2022.
Twelve months ended Dec. 31, 2023 2022 2021 Sales/Cost of Submission $ 1.3 $ 1.2 $ 1.1 Cost of Submission $ 563,552 $ 644,706 $ 804,007 Cost Per Submission $ 683 $ 747 $ 732 Sales/Cost of Submission was $1.3 and $1.2 for the twelve months ended December 31, 2023 and 2022, respectively.
The following are our Direct Operating Cost of Submission (in thousands) and Sales/Direct Operating Cost of Submission for the periods presented: Twelve months ended Dec. 31, 2024 2023 2022 Direct Operating Cost of Submission $ 587,371 $ 563,552 $ 644,706 Sales/Direct Operating Cost of Submission 1.4 1.3 1.2 The increase in Sales/Direct Operating Cost of Submission compared to the prior year was primarily attributable to improvements in agent productivity through enhanced training programs and investment in our technology.
The remaining unpaid balance on the Term Loan Facilities, together with all accrued and unpaid interest thereon, is due and payable on or prior to September 13, 2025. Mandatory Prepayments During the second quarter of 2023, the Company made a $14.0 million mandatory prepayment to its lenders in connection with fiscal year 2022.
Mandatory Prepayments Subject to the terms of the Credit Agreement, the lenders accepted the Company’s offer of an Excess Cash Flow prepayment (as defined in the Credit Agreement prior to the Effective Date of the Amended and Restated Credit Agreement) in connection with fiscal year 2022, and as such, the Company paid $14.0 million during the second quarter of 2023.
The following table presents the Sales per Submission for the periods presented: Sales Per Submission Twelve months ended Dec. 31, 2023 2022 $ Change % Change $ 866 $ 915 $ (49) (5.3) % The decrease for the twelve months ended December 31, 2023 compared to the prior year period was primarily driven by continued pressures on LTV due to increased consumer shopping behavior and an increased constraint on agency commission, partially offset by an increase in commission rates.
For more information on the Company’s agency and non-agency revenue, refer to Note 10, “Revenue.” The following table presents the Sales per Submission for the periods presented: Sales Per Submission Twelve months ended Dec. 31, 2024 2023 $ Change % Change $ 781 $ 866 $ (85) (9.8) % GoHealth, Inc. 2024 Form 10-K 52 The decrease for the twelve months ended December 31, 2024 compared to the prior year period was primarily attributable to a shift from non-agency to agency revenue as a result of changing carrier mix within the non-agency channel.